Tradestie Institutional Equity Comparison Engine

TAK vs ARCT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TAK Overall Edge

TAK Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ARCT counters with relative strength in Valuation. Fundamentally, TAK trades at 12.7x Forward P/E with 16.6% operating margin (+6.7% YoY revenue) versus ARCT at 2.5x Forward P/E and -311.2% operating margin (+6.7% YoY). In options structure, TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against ARCT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ARCT
TAK 12.7x vs ARCT 2.5x Fwd P/E
Growth & Margin Winner TAK
Op Margin 16.6% vs -311.2% ยท YoY +6.7% vs +6.7%
Momentum & Technical Winner TAK
1Y +51.8% vs +10.8% ยท 52W Pos 97% vs 25%
Options & Structure Winner TAK
UNCLASSIFIED (5th %ile IV) vs BREAKDOWN (7th %ile IV)
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
ARCT NASDAQ
Arcturus Therapeutics Holdings Inc. Common Stock
Pharmaceutical Preparations
$8.61
+2.99% 1D
Market Cap $241.0M
1M Return -16.73%
1Y Return +10.81%
Forward P/E 2.5x
Unified AI Score
56.8 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 72.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TAK +51.79% ARCT +10.81% Spread: +40.98 pp (TAK Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TAK TTM Op. Margin: 16.6% ARCT TTM Op. Margin: -311.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs ARCT. Trailing 12-month operating profitability (TAK 16.6% vs ARCT -311.2%) and valuation multiples (TAK 12.7x vs ARCT 2.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TAK (6) vs ARCT (3)
Institutional Metric TAK ARCT Criterion Row Winner
Market Capitalization Scale $67.5B $241.0M Larger Scale TAK
Trailing P/E Ratio Valuation N/M 2.5x Lower Multiple ARCT
Forward P/E Ratio Valuation 12.7x 2.5x Lower Multiple ARCT
Revenue Growth (YoY) Growth +6.7% +6.7% Higher Growth Tie
Operating Margin (TTM) Profitability 16.6% -311.2% Higher Margin TAK
Net Profit Margin Profitability 0.9% -285.9% Higher Margin TAK
Return on Equity (ROE) Capital Efficiency 0.6% -44.4% Higher ROE TAK
52-Week Range Position Momentum 97% ($14โ€“$22) 25% ($6โ€“$18) Stronger Trend TAK
Beta / 30D Volatility Risk Regime -0.02ฮฒ ยท 22% Vol 2.03ฮฒ ยท 127% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 47.7 / 100 (HOLD) 56.8 / 100 (HOLD) Higher Composite ARCT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TAK vs ARCT Buy Guide
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ARCT BREAKDOWN
42d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live ARCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TAK nor ARCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.